A Phase 3 Randomized, Open-Label, Multi-Center, Global Study of Durvalumab in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)

Trial Profile

A Phase 3 Randomized, Open-Label, Multi-Center, Global Study of Durvalumab in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEPTUNE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jan 2017 According to an AstraZeneca media release, the company anticipates to expanded this trial with local patients and readout the OS data in 2018 from the global cohort to support regulatory submission of durvalumab + tremelimumab in China.
    • 04 Nov 2016 Planned number of patients changed from 960 to 1330.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top